Biotech Values

[DewDiligence]

>…that is part of the point David Miller was making, namely the [biogenerics] field will very quickly get crowded.<

I did not see that specific point made in DM’s write-up but, if it had been, it would only have added to the idiocy.

Crowded? There are probably fewer than half a dozen companies who have the resources and the know-how to be serious players in biogenerics.